From: Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms
Total number of CYC treated patients, n | 10 |
Male sex | 70% |
Median Age at Diagnosis of KD (range) | 2 years (4 months – 5 years) |
Race | |
• White | • 4 |
• Asian | • 2 |
• Hispanic | • 3 |
• Not available | • 1 |
Complete KD criteria | 50% |
Median Day of Illness at 1st IVIG (range) | 7 (4–10) |
Median Day of Illness at CYCa (range) | 22.5 (10–36) |
Two doses of CYC | 30% |
Adjunctive Therapies before CYC | |
• Glucocorticoids | • 100% |
• Infliximab | • 40% |
• Cyclosporine A | • 20% |
• Anakinra | • 10% |
Median Baseline LADb Z score (range) | 3.8 (0.68–13.4) |
Median Baseline RCAc Z score (range) | 2.1 (0.1–12.16) |
Median LAD Z Max during admission (range)d | 15.7 (4.7–29.6) |
Median RCA Z Max during admission (range) d | 11.8 (2.0–21.06) |
Number of patients with bilateral aneurysms (n, %) | 9 (90%) |
Number of patients with giant aneurysms (n, %) | 8 (80%) |